



Australian Government
Department of Health and Ageing
Therapeutic Goods Administration

File No.: 2009/002051

AIVC Recommendations for the Composition of Influenza Vaccine for 2010

The meeting of the Australian Influenza Vaccine Committee (AIVC) on Influenza Vaccines was convened on 2nd October 2009.

The committee considered information on international surveillance by WHO, recent data from Australia, New Zealand, South Africa and Argentina on epidemiology and strain characterisation, and the recommendations of the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere, held in Melbourne on 17-19 September.

The Committee agreed to adopt the September WHO recommendations. The influenza vaccine components for year 2010 season should contain the following:

A (H1N1):	an A/California/7/2009 (H1N1) - like strain,	15 µg HA per dose
A (H3N2):	an A/Perth/16/2009 (H3N2) - like strain,	15 µg HA per dose
B:	a B/Brisbane/60/2008 - like strain,	15 µg HA per dose

The following viruses are suitable vaccine strains:

- A/California/7/2009 (H1N1) (NYMC X-179A, NYMC X-181, NYMC X-181A, NIBRG-121, NIBRG-121xp)
- A/Perth/16/2009 (H3N2) -like strain
- B/Brisbane/60/2008

- The SRID reference antigen for A/California/7/2009 (H1N1) is available from TGA for NYMC X-179A and NYMC X-181 reassortants or NIBSC (UK) for NIBRG-121 and NIBRG-121xp reassortants. Antisera suitable for use with all these reassortants is available from NIBSC.
- The SRID reference standard reagents for A/Perth/16/2009 (H3N2) will be available from TGA and NIBSC.
- The SRID reference standard reagents for B/Brisbane/60/2008 are available from TGA and NIBSC.

Yours sincerely,

A/Prof Gary Grohmann
AIVC Chair
Immunobiology
OLSS
2 October 2009